化脓性扁桃体炎：新靶点和新疗法

IF 8.6 1区医学 Q1 DERMATOLOGY American Journal of Clinical Dermatology Pub Date : 2024-07-26 DOI:10.1007/s40257-024-00880-1

Julia L. Gao, Tracey S. Otto, Martina L. Porter, Alexa B. Kimball

{"title":"化脓性扁桃体炎：新靶点和新疗法","authors":"Julia L. Gao, Tracey S. Otto, Martina L. Porter, Alexa B. Kimball","doi":"10.1007/s40257-024-00880-1","DOIUrl":null,"url":null,"abstract":"<div><p>Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that can be challenging to treat. Biologics and targeted small molecules have become an increasingly popular area of investigation for therapeutic development for moderate-to-severe HS, though only three biologics—adalimumab, secukinumab, and bimekizumab—have received US Food and Drug Administration (FDA) or European Medicines Evaluation Agency approval for treating HS. Promising agents under investigation are targeting interleukin 17A/F, JAK/STAT pathway, interleukin 36, interleukin 1, and more.</p></div>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"25 5","pages":"765 - 778"},"PeriodicalIF":8.6000,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hidradenitis Suppurativa: New Targets and Emerging Treatments\",\"authors\":\"Julia L. Gao, Tracey S. Otto, Martina L. Porter, Alexa B. Kimball\",\"doi\":\"10.1007/s40257-024-00880-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that can be challenging to treat. Biologics and targeted small molecules have become an increasingly popular area of investigation for therapeutic development for moderate-to-severe HS, though only three biologics—adalimumab, secukinumab, and bimekizumab—have received US Food and Drug Administration (FDA) or European Medicines Evaluation Agency approval for treating HS. Promising agents under investigation are targeting interleukin 17A/F, JAK/STAT pathway, interleukin 36, interleukin 1, and more.</p></div>\",\"PeriodicalId\":7706,\"journal\":{\"name\":\"American Journal of Clinical Dermatology\",\"volume\":\"25 5\",\"pages\":\"765 - 778\"},\"PeriodicalIF\":8.6000,\"publicationDate\":\"2024-07-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Clinical Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s40257-024-00880-1\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Clinical Dermatology","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s40257-024-00880-1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

化脓性扁平湿疹（HS）是一种慢性炎症性皮肤病，治疗难度很大。生物制剂和靶向小分子药物已成为治疗中重度HS的一个日益热门的研究领域，但目前只有三种生物制剂--阿达木单抗、secukinumab和bimekizumab--获得了美国食品药品管理局（FDA）或欧洲药品评价局的批准用于治疗HS。针对白细胞介素 17A/F、JAK/STAT 通路、白细胞介素 36、白细胞介素 1 等的药物正在研究中，前景看好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Hidradenitis Suppurativa: New Targets and Emerging Treatments

Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that can be challenging to treat. Biologics and targeted small molecules have become an increasingly popular area of investigation for therapeutic development for moderate-to-severe HS, though only three biologics—adalimumab, secukinumab, and bimekizumab—have received US Food and Drug Administration (FDA) or European Medicines Evaluation Agency approval for treating HS. Promising agents under investigation are targeting interleukin 17A/F, JAK/STAT pathway, interleukin 36, interleukin 1, and more.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

American Journal of Clinical Dermatology 医学-皮肤病学

CiteScore

15.20

自引率

2.70%

发文量

审稿时长

>12 weeks

期刊介绍： The American Journal of Clinical Dermatology is dedicated to evidence-based therapy and effective patient management in dermatology. It publishes critical review articles and clinically focused original research covering comprehensive aspects of dermatological conditions. The journal enhances visibility and educational value through features like Key Points summaries, plain language summaries, and various digital elements, ensuring accessibility and depth for a diverse readership.